Diabetes, Vol 42, Issue 12 1753-1759, Copyright © 1993 by American Diabetes Association

ARTICLES

Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients

AJ Krentz, B Dousset, D Mayer, P McMaster, J Buckels, R Cramb, JM Smith and M Nattrass
Diabetic Clinic, General Hospital, Birmingham, United Kingdom.

Postoperative diabetes is a reported feature of the immunosuppressive agents cyclosporin A and FK 506. To date, however, no randomized comparative studies of the metabolic effects of these two drugs have been performed. In this study, extended (300 min) oral glucose tolerance tests (75 g) were performed a median of 8 mo (range 5-9 mo) postoperatively in 20 clinically stable liver transplant recipients randomly allocated to maintenance immunosuppression with either cyclosporin A (with or without azathioprine) or FK 506. None of the patients had clinically overt diabetes antedating transplantation. To avoid the confounding effects of corticosteroids, prednisolone was withdrawn at least 6 wk beforehand in each case. Ten healthy volunteers matched for age and body mass index served as control subjects. Overall blood glucose concentrations after the glucose challenge were significantly elevated in both groups of transplant recipients (P < 0.005 and P < 0.001 for cyclosporin A and FK 506 treatment groups, respectively) compared with the healthy control subjects. Venous whole-blood glucose concentration (mean +/- SE) 120 min after the ingestion of oral glucose was significantly higher in both the cyclosporin A (P < 0.05) and FK 506 (P < 0.01) treatment groups compared with the control subjects (6.6 +/- 0.5 vs. 8.8 +/- 0.9 vs. 5.2 +/- 0.2 mM, respectively). According to 1985 WHO criteria, 4 of 10 cyclosporin A-treated patients had impaired glucose tolerance, whereas 3 of 10 FK 506-treated patients had diabetes with 4 others having impaired glucose tolerance.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. D. Bloom, V. Rao, F. Weng, R. A. Grossman, D. Cohen, and K. C. Mange Association of Hepatitis C with Posttransplant Diabetes in Renal Transplant Patients on Tacrolimus J. Am. Soc. Nephrol., May 1, 2002; 13(5): 1374 - 1380. [Abstract] [Full Text] [PDF]

				M. Dufer, P. Krippeit-Drews, N. Lembert, L.-A. Idahl, and G. Drews Diabetogenic Effect of Cyclosporin A Is Mediated by Interference with Mitochondrial Function of Pancreatic B-Cells Mol. Pharmacol., October 1, 2001; 60(4): 873 - 879. [Abstract] [Full Text] [PDF]

				G. Filler, I. Neuschulz, I. Vollmer, P. Amendt, and B. Hocher Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients Nephrol. Dial. Transplant., June 1, 2000; 15(6): 867 - 871. [Abstract] [Full Text] [PDF]